Market Cap 434.57M
Revenue (ttm) 0.00
Net Income (ttm) -15.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 230,900
Avg Vol 229,846
Day's Range N/A - N/A
Shares Out 6.68M
Stochastic %K 79%
Beta 1.46
Analysts Strong Sell
Price Target $110.85

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imagi...

Industry: Biotechnology
Sector: Healthcare
Phone: 847 388 0349
Address:
1000 Skokie Boulevard, Suite 350, Wilmette, United States
Arcides
Arcides Jan. 13 at 2:17 AM
$MNPR looks like a good time to buy monopar
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 11 at 9:38 PM
$RADX strains more ownership in Radiopharm Ventures now at 87.5% yielding a basket of new therapeutics. B7-H3 created with the collaboration is now Phase 1 approved. Radiopharm Ventures = MD Anderson + Radiopharm Theranostics. Trading at 5-6% value of $AKTS with a more advanced diversified pipeline. $IMNM $MNPR
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 5 at 12:35 PM
$MNPR RSI: 27.35, MACD: -3.8831 Vol: 5.07, MA20: 71.67, MA50: 78.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
UgoGreg
UgoGreg Jan. 1 at 11:07 PM
$MNPR https://youtu.be/ygBN8MilTyc
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 30 at 2:42 PM
$30 target for Radiopharm Theranostics. Rad101 reached 92% on potentially 3rd largest radiopharm imaging brain mets phase 2b. Lantheus owns 14.5% $RADX $CATX $MNPR $PYXS
1 · Reply
TheVariableV
TheVariableV Dec. 25 at 9:49 AM
$MNPR Upside depends on translating ambition into measurable cadence, with macro volatility magnifying operational missteps. The upside case requires evidence, not projection.
0 · Reply
trading_momentum_x
trading_momentum_x Dec. 23 at 3:09 AM
$MNPR has reversed sharply off the 64–65 demand zone, forming a clear sequence of higher lows and pushing back toward equilibrium. The bounce is impulsive relative to the prior decline, suggesting active dip-buying rather than a passive drift. Price is now testing the 72–73 equilibrium / mid-range area, where short-term pauses are likely. The larger overhead 79–80 supply zone remains the key upside cap and will likely attract sellers on any continuation. Key levels: Resistance: 72–73 initially, then 79–80 Support: 68–69, followed by 65–64 if momentum fades Bottom line: MNPR is in a strong short-term recovery off demand, but it is now entering a decision area. Acceptance above the low-70s would keep the rebound intact; failure would shift the move back into corrective territory.
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 3:18 PM
Biotech boom in 2025: Can $IONS, $GPCR, $MNPR, and $KOD keep the momentum? IONS soared 120.5% with strong pipeline progress and favorable regulatory developments. GPCR up 127.2% on promising obesity drug data. MNPR skyrocketed 185.9% fueled by positive investor expectations regarding its lead candidate. KOD surged 181.1% on solid late-stage pipeline potential. See the full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-body-25804&ADID=SYND_STOCKTWITS_TWEET_2_2807434_BODY_25804
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 2:18 PM
These biotech names more than doubled in 2025 — momentum or mania? $IONS, $GPCR, $MNPR, and $KOD all surged over 100% in 2025, fueled by policy clarity, a revival in M&A activity, and key clinical wins pushing biotech momentum into 2026. Which of these winners still has room to run — and which could fade? Full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-teaser-25785&ADID=SYND_STOCKTWITS_TWEET_2_2807434_TEASER_25785
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 20 at 8:34 PM
How Radioisotopes Are Being Used to De-Risk Antibody-Drug Conjugate (ADC) Development $RADX $IMNM $MNPR $PYXS https://blog.championsoncology.com/blog/how-radiopharmaceuticals-are-being-used-to-de-risk-antibody-drug-conjugate-adc-development
0 · Reply
Latest News on MNPR
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025, 2:30 AM EDT - 9 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025


Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule


Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split


Monopar and NorthStar Amend & Extend Collaboration

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Monopar and NorthStar Amend & Extend Collaboration


Monopar Announces CFO Succession

May 24, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces CFO Succession


Arcides
Arcides Jan. 13 at 2:17 AM
$MNPR looks like a good time to buy monopar
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 11 at 9:38 PM
$RADX strains more ownership in Radiopharm Ventures now at 87.5% yielding a basket of new therapeutics. B7-H3 created with the collaboration is now Phase 1 approved. Radiopharm Ventures = MD Anderson + Radiopharm Theranostics. Trading at 5-6% value of $AKTS with a more advanced diversified pipeline. $IMNM $MNPR
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 5 at 12:35 PM
$MNPR RSI: 27.35, MACD: -3.8831 Vol: 5.07, MA20: 71.67, MA50: 78.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
UgoGreg
UgoGreg Jan. 1 at 11:07 PM
$MNPR https://youtu.be/ygBN8MilTyc
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 30 at 2:42 PM
$30 target for Radiopharm Theranostics. Rad101 reached 92% on potentially 3rd largest radiopharm imaging brain mets phase 2b. Lantheus owns 14.5% $RADX $CATX $MNPR $PYXS
1 · Reply
TheVariableV
TheVariableV Dec. 25 at 9:49 AM
$MNPR Upside depends on translating ambition into measurable cadence, with macro volatility magnifying operational missteps. The upside case requires evidence, not projection.
0 · Reply
trading_momentum_x
trading_momentum_x Dec. 23 at 3:09 AM
$MNPR has reversed sharply off the 64–65 demand zone, forming a clear sequence of higher lows and pushing back toward equilibrium. The bounce is impulsive relative to the prior decline, suggesting active dip-buying rather than a passive drift. Price is now testing the 72–73 equilibrium / mid-range area, where short-term pauses are likely. The larger overhead 79–80 supply zone remains the key upside cap and will likely attract sellers on any continuation. Key levels: Resistance: 72–73 initially, then 79–80 Support: 68–69, followed by 65–64 if momentum fades Bottom line: MNPR is in a strong short-term recovery off demand, but it is now entering a decision area. Acceptance above the low-70s would keep the rebound intact; failure would shift the move back into corrective territory.
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 3:18 PM
Biotech boom in 2025: Can $IONS, $GPCR, $MNPR, and $KOD keep the momentum? IONS soared 120.5% with strong pipeline progress and favorable regulatory developments. GPCR up 127.2% on promising obesity drug data. MNPR skyrocketed 185.9% fueled by positive investor expectations regarding its lead candidate. KOD surged 181.1% on solid late-stage pipeline potential. See the full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-body-25804&ADID=SYND_STOCKTWITS_TWEET_2_2807434_BODY_25804
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 2:18 PM
These biotech names more than doubled in 2025 — momentum or mania? $IONS, $GPCR, $MNPR, and $KOD all surged over 100% in 2025, fueled by policy clarity, a revival in M&A activity, and key clinical wins pushing biotech momentum into 2026. Which of these winners still has room to run — and which could fade? Full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-teaser-25785&ADID=SYND_STOCKTWITS_TWEET_2_2807434_TEASER_25785
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 20 at 8:34 PM
How Radioisotopes Are Being Used to De-Risk Antibody-Drug Conjugate (ADC) Development $RADX $IMNM $MNPR $PYXS https://blog.championsoncology.com/blog/how-radiopharmaceuticals-are-being-used-to-de-risk-antibody-drug-conjugate-adc-development
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 20 at 7:31 PM
$MNPR RADX on Monday now at $5.19 do your DD
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 3:13 AM
0 · Reply
GoldenStripe
GoldenStripe Dec. 7 at 3:36 PM
0 · Reply
ssdsddssd2
ssdsddssd2 Dec. 7 at 2:30 PM
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 2 at 1:45 AM
$RADX Radiopharm Theranostics $30 target at Jones Trading $NNE $ASPI $MNPR
3 · Reply
RadioIsotope25
RadioIsotope25 Nov. 25 at 3:44 PM
Therapeutic Radiopharmaceuticals: Download 2025 Global Report - Clinical Trials Arena $RADX $CBSR $CATX $MNPR https://www.clinicaltrialsarena.com/sponsored/therapeutic-radiopharmaceuticals-download-2025-global-report/
0 · Reply
ScreenerIQ
ScreenerIQ Nov. 23 at 5:49 PM
Some Stocks showing strong relative strength. Filtered on '5-Day Return'. Please DYOResearch. Some examples: $EYPT $MNPR $NTRA $DY #StockMarket #investing #Trading
0 · Reply
Stanfordfund
Stanfordfund Nov. 22 at 1:20 PM
$MNPR Never sell!
0 · Reply
milanmoses
milanmoses Nov. 19 at 5:14 PM
Big eyes on $MNPR: their Wilson disease candidate + radiopharma combo is rare.
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 19 at 2:48 PM
0 · Reply
notreload_ai
notreload_ai Nov. 14 at 4:43 PM
$BTM $FISV $MNPR $PGR $TCRX -- MarketBeat
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 11:54 AM
Raymond James has adjusted their stance on Monopar Therapeutics ( $MNPR ), setting the rating to Outperform with a target price of 142 → 123.
0 · Reply